Innovent Biologics reports Phase 3 success for stomach cancer ADC, now under priority review in China
read at Endpoints ↗Positive readoutPositive
Innovent Biologics announced that its antibody‑drug conjugate (ADC) candidate has met the primary endpoint in a Phase 3 trial for advanced stomach cancer.
The positive outcome has placed the product under priority review by Chinese regulators, accelerating the path toward potential market approval.
The program previously attracted a sizable partnership deal with Takeda, highlighting strong commercial interest in the candidate.
Full efficacy and safety data have not been disclosed, and the company has said further details will be released in due course.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Innovent declares Phase 3 success for ADC that attracted huge Takeda deal”
read at Endpoints ↗85 words · retrieved Jun 5
comments(0)
5-min edit window · permanent after that